

Therapie der Migräneattacke und Migräneprophylaxe*

Hans Christoph Diener, Essen, für die Expertengruppe**

Literatur

- Ahonen, K., M. Hamalainen, H. Rantala et al. (2004): Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. *Neurology* 62, 883–887.
- Amery, W. K., L. I. Caers, T. J. L. Aerts (1985): Flunarizine, a calcium entry blocker in migraine prophylaxis. *Headache* 25, 249–254.
- Andrasik, F. (2003): Behavioral treatment approaches to chronic headache. *J. Neurol. Sci.* 24, Suppl. 2, S80–S85.
- Bakal, D. A., S. Demjen, J. A. Kaganov (1981): Cognitive behavioral treatment of chronic headache. *Headache* 21, 81–86.
- Balkan, S., B. Aktekin, Z. Önal (1994): Efficacy of flunarizine in the prophylactic treatment of migraine. *Gazi Medical Journal* 5, 81–84.
- Bassi, P., L. Brunati, B. Rapuzzi et al. (1992): Low dose flunarizine in the prophylaxis of migraine. *Headache* 32, 390–392.
- Bates, D., E. Ashford, R. Dawson et al. (1994): Subcutaneous sumatriptan during the migraine aura. *Neurology* 44, 1587–1592.
- Becker, W. J., on behalf of the Study Group (1995): A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. *Cephalalgia* 15 (Suppl. 14), 271–276.
- Bernstein, D. A., T. D. Borkovec (1975): Entspannungstraining. *Handbuch der Progressiven Muskelrelaxation*. Pfeiffer, München.
- Blachard, E. B., A. E. Taylor, M. P. Dentinger (1992): Preliminary results from the self-regulatory treatment of high medication consumption headache. *Biofeedback Self Reg.* 17, 179–202.
- Blanchard, E. B., F. Andrasik (1985): Management of chronic headaches. A psychological approach. Pergamon Press; Elmsford NY.
- Bono, G., G. C. Manzoni, N. Martucci et al. (1985): Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. *Cephalalgia* 5 Suppl. 2, 155–158.
- Brandes, J. L., J. Saper, M. Diamond et al. (2004a): Topiramate for migraine prevention: a randomized controlled trial. *JAMA* 291, 965–973.
- Brandes, J. L., W. H. Visser, M. V. Farmer et al. (2004b): Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. *Headache* 44, 581–586.
- Burstein, R., B. Collins, M. Jakubowski (2004): Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. *Ann. Neurol.* 55, 19–26.
- Bussone, G., R. Cerbo, N. Martucci et al. (1999): Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. *Headache* 39, 426–431.
- Campbell, J. K., D. B. Penzien, E. M. Wall (2004): Evidence-based guidelines for migraine headaches: behavioral and psychological treatments. www.aan.com/public.
- Centonze, V., P. Tesauro, D. Magrone et al. (1985): Efficacy and tolerability of flunarizine in the prophylaxis of migraine. *Cephalalgia* 2, 163–168.
- Chabriat, H., J. Danchot, P. Gripon et al. (1994): Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. *Cephalalgia* 14, 297–300.
- Charlesworth, B., A. Dowson, A. Purdy et al. (2003): Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. *CNS Drugs* 17, 653–667.
- Christie, S., H. Göbel, V. Mateos et al. (2002): Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/cafeine in migraine. *Eur. Neurol.* 49, 20–29.
- Couch, J. R., D. K. Ziegler, R. Hassanein (1976): Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant drugs. *Neurology* 26, 121–127.
- Couch, J. R., R. S. Hassanein (1979): Amitriptyline in migraine prophylaxis. *Arch. Neurol.* 36, 695–699.
- Dahlöf, C., R. Björkman (1993): Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. *Cephalalgia* 13, 117–123.
- Dahlöf, C., R. Cady, A. C. Poole et al. (2004): Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid release tablets: results of two replicate randomised, placebo-controlled studies. *Headache Care* 1, 277–280.
- De Lignieres, B., P. Mauvais-Javis, J. M. L. Mas et al. (1986): Prevention of menstrual migraine by percutaneous oestradiol. *BMJ* 293, 1540.
- Denecke, H., B. Kröner-Herwig (2000): Kopfschmerztherapie mit Kindern und Jugendlichen. Hogrefe, Göttingen.
- Dennerstein, L., C. Morse, G. Burrows et al. (1988): Menstrual migraine: a double blind trial of percutaneous oestradiol. *Gynecol. Endocrinol.* 2, 113–120.
- Diamond, M., J. Hettiarachchi, B. Hilliard et al. (2004): Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. *Headache* 44, 209–216.
- Diamond, S., J. L. Medina (1976): Double blind study of propranolol for migraine prophylaxis. *Headache* 16, 24–27.
- Diamond, S., H. Schenbaum (1983): Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. *Headache* 23, 39–42.
- Diamond, S., F. G. Freitag (1993): A double blind trial of flunarizine in migraine prophylaxis. *Headache Quarterly Current Treatment and Research* 4, 169–172.
- Dichgans, J., H. C. Diener, W. D. Gerber et al. (1984): Analgetika-induzierter Dauerkopfschmerz. *Dtsch. med. Wschr.* 109, 369–373.
- Diener, H. C., M. Föh, C. Iaccarino et al. (1996): Cyclandelate in the prophylaxis of migraine: A randomized, parallel, double-blind study in comparison with placebo and

***Nachdruck aus: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie“. Leitlinien für Diagnostik und Therapie in der Neurologie. 3., aktualisierte und erweiterte Auflage, Georg Thieme Verlag, Stuttgart, 2005.**

**Expertengruppe

Für die DGN

Hans-Christoph Diener, Universitätsklinik für Neurologie Essen

Volker Limmroth, Universitätsklinik für Neurologie Essen

Günther Fritsche, Universitätsklinik für Neurologie Essen

Kay Brune, Institut für Pharmakologie und Toxikologie der Universität Erlangen

Volker Pfaffenrath, Neurologe, München

Für die DMKG

Peter Kropp, Institut für Medizinische Psychologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel

Arne May, Neurologische Universitätsklinik Hamburg

Andreas Straube, Klinikum Großhadern, Neurologische Klinik der Universität München

Stefan Evers, Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster

Federführend: Prof. Dr. Hans-Christoph Diener, Universitätsklinik für Neurologie, Hufelandstr. 55, 45147 Essen, E-Mail: h.diener@uni-essen.de

- propranolol. *Cephalalgia* 16, 441–447.
35. Diener, H. C., for the ASASUMAMIG Study Group (1999): Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. *Cephalalgia* 19, 581–588.
 36. Diener, H. C., K. Brune, W. D. Gerber et al. (2000): Therapie der Migräneattacke und Migräneprophylaxe. Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG). *Akt. Neurologie* 27, 273–282.
 37. Diener, H. C., E. Hartung, J. Chrubasik et al. (2001a): A comparative study of acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. *Cephalalgia* 21, 140–144.
 38. Diener, H. C., P. Krupp, T. Schmitt et al. (2001b): Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. *Cephalalgia* 21, 66–70.
 39. Diener, H., J. Matias-Guiu, E. Hartung et al. (2002a): Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. *Cephalalgia* 22(3), 209–221.
 40. Diener, H. C., A. Reches, J. Pascual et al. (2002b): Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafertog) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. *Europ. Neurol.* 47, 99–107.
 41. Diener, H. C., die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie, editors (2003): Leitlinien für Diagnostik und Therapie in der Neurologie, 2. ed. Thieme, Stuttgart.
 42. Diener, H., V. Limmroth (2004): Prevention of migraine: betablockers and amine agonists: efficacy. In: Olesen, J., S. Silberstein, P. Tfelt-Hansen, editors: Preventive pharmacotherapy of headache disorders. Oxford University Press, Oxford, 59–66.
 43. Diener, H. C., G. Bussone, H. de Liano et al. (2004a): Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. *Cephalalgia* 24, 947–954.
 44. Diener, H. C., A. Eikermann, U. Gessner et al. (2004b): Efficacy of 1000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. *Eur. Neurol.* 52, 50–56.
 45. Diener, H. C., V. W. Rahlfs, U. Danesch (2004c): The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: Reanalysis of efficacy criteria. *Eur. Neurol.* 51, 89–97.
 46. Diener, H. C., P. Tfelt-Hansen, C. Dahlöf et al. (2004d): Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. *J. Neurol.* 251: 943–950.
 47. Diener, H. C., V. Pfaffenrath, L. Pageler et al. (2005a): The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. *Cephalalgia* 25, in press.
 48. Diener, H. C., V. Pfaffenrath, J. Schnitker, M. Friede, H.H Henneicke-von Zepelin, on behalf of the Investigators. (2005b): Efficacy and safety of 6.25mg tid feverfew-CO₂-extract (MIG-99) in mi-graine prevention – A randomised, double-blind, multicentre, placebo-controlled study. *Cephalalgia*; in press.
 49. Dowson, A., H. Massiou, J. Lainez et al. (2004): Almotriptan improves response rates when treatment is within 1 hour of migraine onset. *Headache* 44, 318–322.
 50. Ellis, G. L., J. Delaney, D. A. DeHart et al. (1993): The efficacy of metoclopramide in the treatment of migraine headache. *Annals of Emergency Medicine* 22, 191–195.
 51. Ernst, E. (1999): Homeopathic prophylaxis of headache and migraine. A systematic review. *J. Pain Symptom Manage* 18, 353–357.
 52. Evers, S., J. Vollmer-Haase, S. Schwaag et al. (2004): Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. *Cephalalgia* 24, 838–843.
 53. Ferrari, M. D., M. H. James, D. Bates et al. (1994): Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. *Cephalalgia* 14, 330–338.
 54. Ferrari, M. D. (1999): How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. *Cephalalgia* 19 (Suppl. 23), 2–8.
 55. Ferrari, M. D., K. I. Roon, R. B. Lipton et al. (2001): Oral triptans (serotonin 5-HT_{1B/1D} agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet* 358, 1668–1675.
 56. Fox, A. W., C. D. Chambers, P. O. Anderson et al. (2002): Evidence-based assessment of pregnancy outcome after sumatriptan exposure. *Headache* 42, 8–15.
 57. Freitag, F. G., S. Diamond, M. Diamond (1991): A placebo controlled trial of flunarizine in migraine prophylaxis. *Cephalalgia* 11 (Suppl. 11), 157–158.
 58. Freitag, F., S. Collins, H. Carlson et al. (2002): A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology* 58, 1652–1659.
 59. Frettlöh, J., C. Franz, C. Jäkle et al. (1998): Das Manual. In: Basler, H. D., B. Kröner-Herwig, editors: Psychologische Therapie bei Kopf- und Rückenschmerzen. Quintessenz, München.
 60. Gawel, M. J., J. Kreeft, R. F. Nelson et al. (1992): Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. *Can. J. Neurol. Sci.* 19, 340–345.
 61. Geraud, G., A. Compagnon, A. Rossi et al. (2002): Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. *Eur. Neurol.* 47, 88–98.
 62. Goadsby, P. B., R. B. Lipton, M. D. Ferrari (2002): Migraine: current understanding and management. *N. Engl. J. Med.* 346, 257–270.
 63. Goadsby, P. J. (1997): Role of naratriptan in clinical practice. *Cephalalgia* 17, 472–473.
 64. Goldstein, D. J., W. W. Offen, E. G. Klein et al. (2001): Lanepitant, an NK-1 antagonist, in migraine prevention. *Cephalalgia* 21, 102–106.
 65. Goldstein, J., R. Ryan, K. Jiang et al. (1998): Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. *Headache* 38, 737–747.
 66. Grazi, L., F. Andrasik, D. D'Amico et al. (2002): Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. *Headache* 42, 483–490.
 67. Hall, G., M. Brown, J. Mo et al. (2004): Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. *Neurology* 62, 563–568.
 68. Hämäläinen, M. L., K. Hoppu, P. Santavuori (1997): Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? *Neurology* 48, 1100–1103.
 69. Havanka-Kanninen, H., E. Hokkanen, V. V. Myllylä (1988): Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. *Headache* 28, 607–611.
 70. Havanka-Kanninen, H. (1989): Treatment of acute migraine attack: ibuprofen and placebo compared. *Headache* 29, 507–509.
 71. Hermann, C., M. Kim, E. B. Blanchard (1995): Behavioural and prophylactic intervention studies of pediatric migraine: an exploratory meta-analysis. *Pain* 60, 239–256.
 72. Holroyd, K., F. Andrasik (1982): Cognitive-behavioral approach to recurrent tension and migraine headache. In: Kendall, P. C., editor: *Advances in Cognitive-Behavioral Research and Therapy*. Academic Press, New York, 275–320.
 73. Holroyd, K. A., D. B. Penzien, G. E. Cordingley (1991): Propranolol in the management of recurrent migraine: a meta-analytic review. *Headache* 31, 333–340.
 74. Horton, B. T., G. A. Peters (1963): Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. *Headache* 3, 214–226.
 75. Källen, B., P. E. Lygner (2001): Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. *Headache* 41, 351–356.
 76. Kangasniemi, P., C. Hedman (1984): Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. *Cephalalgia* 4, 91–96.
 77. Kaniecki, R. G. (1997): A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Arch. Neurol.* 54, 1141–1145.
 78. Karachalios, G. N., A. Fotiadou, N. Chrisikos et al. (1992): Treatment of acute migraine attack with diclofenac sodium: A double-blind study. *Headache* 32, 98–100.
 79. Katsarava, Z., G. Fritsche, H. C. Diener et al.

- (2000): Drug-induced headache (DIH) following the use of different triptans. *Cephalalgia* 20, 293 [abstract].
80. Klapper, J., on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997): Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia* 17, 103–108.
 81. Kloster, R., K. Nestvold, S. T. Vilming (1992): A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. *Cephalalgia* 12, 169–171.
 82. Koseoglu, E., A. Akboyraz, A. Soyuer et al. (2003): Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. *Cephalalgia* 23, 972–976.
 83. Kröner-Herwig, B., U. Ehlert (1992): Relaxation und Biofeedback in der Behandlung von chronischen Kopfschmerzen bei Kindern und Jugendlichen. *Schmerz* 6, 171–181.
 84. Krymchantowski, A. V., M. Adriano, D. Fernandes (1999): Tolfenamic acid decreases migraine recurrence when used with sumatriptan. *Cephalalgia* 19, 186–187.
 85. Krymchantowski, A. V., J. Barbosa (2002): Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. *Cephalalgia* 22(4), 309–312.
 86. Lampl, C., A. Buzath, D. Klinger et al. (1999): Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. *Cephalalgia* 19, 58–63.
 87. Limmroth, V., S. Kazarawa, G. Fritsche et al. (1999a): Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. *Lancet* 353, 378.
 88. Limmroth, V., A. May, H. C. Diener (1999b): Lysine-acetylsalicylic acid in acute migraine attacks. *Eur. Neurol.* 41, 88–93.
 89. Lipton, R. B., W. F. Stewart, R. E. Ryan et al. (1998): Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - Three double-blind, randomized, placebo-controlled trials. *Arch. Neurol.* 55, 210–217.
 90. Lipton, R., A. Scher, K. Kolodner et al. (2002): Migraine in the United States: epidemiology and patterns of health care use. *Neurology* 58(6), 885–894.
 91. Louis, P. (1981): A double-blind placebo-controlled prophylactic study of flunarizine in migraine. *Headache* 21, 235–239.
 92. Ludin, H.-P. (1989): Flunarizine and propranolol in the treatment of migraine. *Headache* 29, 218–223.
 93. McDavis, H. L., J. Hutchison (1999): Frovatriptan Phase III Investigators. Frovatriptan - a review of overall clinical efficacy. *Cephalalgia* 19, 363–364.
 94. Mathew, N. T., R. Kurman, F. Perez (1990): Drug induced refractory headache - clinical features and management. *Headache* 30, 634–638.
 95. Mathew, N. T., A. Rapoport, J. Saper et al. (2001): Efficacy of gabapentin in migraine prophylaxis. *Headache* 41, 119–128.
 96. Maytal, J., M. Young, A. Shechter et al. (1997): Pediatric migraine and the International Headache Society (IHS) criteria. *Neurology* 48, 602–607.
 97. Michultka, D. M., E. B. Blanchard, K. A. Appelbaum et al. (1989): The refractory headache patient. II. High medication consumption (analgesic rebound) headache. *Behav. Res. Ther.* 27, 411–420.
 98. Nadelmann, J. W., J. Stevens, J. R. Saper (1986): Propranolol in the prophylaxis of migraine. *Headache* 26, 175–182.
 99. Nappi, G., G. Sandrini, G. Savoini et al. (1987): Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. *Drugs* 33 (Suppl. 2), 103–109.
 100. Nebe, J., M. Heier, H. C. Diener (1995): Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. *Cephalalgia* 15, 531–535.
 101. Newman, L. C., R. B. Lipton, C. L. Lay et al. (1998): A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. *Neurology* 51, 307–309.
 102. Newman, L., L. K. Mannix, S. Landy et al. (2001): Naratriptan as short-term prophylaxis in menstrually associated migraine: a randomised, double-blind, placebo-controlled study. *Headache* 41, 248–256.
 103. O'Quinn, S., R. L. Davis, D. L. Guttermann et al. (1999): Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. *Cephalalgia* 19, 223–231.
 104. Olesen, C., F. H. Steffensen, H. T. Sorensen et al. (2000): Pregnancy outcome following prescription for sumatriptan. *Headache* 40, 20–24.
 105. Olesen, J., M.-G. Bousser, H. Diener et al. (2004a): The International Classification of Headache Disorders. 2nd Edition. *Cephalalgia* 24 (Suppl. 1), 1–160.
 106. Olesen, J., H. C. Diener, J. Schoenen et al. (2004b): No effect of eletriptan administration during the aura phase of migraine. *Europ. J. Neurol.* 11, 671–677.
 107. Olsson, J. E., H. C. Behring, B. Forssman et al. (1984): Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. *Acta Neurol. Scand.* 70, 160–168.
 108. Peikert, A., C. Wilimzig, R. Köhne-Volland (1996): Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. *Cephalalgia* 16, 257–263.
 109. Pfaffenrath, V., P. Wessely, C. Meyer et al. (1996): Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. *Cephalalgia* 16, 436–440.
 110. Pfaffenrath, V., H. C. Diener, M. Fischer et al. (2002): The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia* 22, 523–532.
 111. Pilgrim, A. J. (1993): The methods used in clinical trials of sumatriptan in migraine. *Headache* 33, 280–293.
 112. Quality Standards Subcommittee of the American Academy of Neurology (1994): Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. *Neurology* 44, 1353–1354.
 113. Rasmussen, B. K., R. Jensen, M. Schroll et al. (1991): Epidemiology of headache in a general population - a prevalence study. *J. Clin. Epidemiol.* 44, 1147–1157.
 114. Ross-Lee, L. M., M. J. Eadie, V. Heazlewood et al. (1983): Aspirin pharmacokinetics in migraine. The effect of metoclopramide. *Eur. J. Clin. Pharmacol.* 24, 777–785.
 115. Ryan, R., A. Elkind, C. C. Baker et al. (1997): Sumatriptan nasal spray for the acute treatment of migraine. *Neurology* 49, 1225–1230.
 116. Sances, G., E. Martignoni, L. Fioroni et al. (1990): Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. *Headache* 30, 705–709.
 117. Scher, A., W. F. Stewart, J. Liberman et al. (1998): Prevalence of frequent headache in a population sample. *Headache* 38, 497–506.
 118. Schoenen, J., M. Lenaerts, E. Bastings (1994): High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. *Cephalalgia* 14, 328–330.
 119. Schoenen, J., J. Jacquy, M. Lenaerts (1997): High-dose power riboflavin as a novel prophylactic antimigraine therapy: results from a double-blind, randomized, placebo-controlled trial. *Cephalalgia* 17, 244.
 120. Schoenen, J., J. Jacquy, M. Lenaerts (1998): Effectiveness of high-dose riboflavin in migraine prophylaxis - A randomized controlled trial. *Neurology* 50, 466–470.
 121. Schrader, H., L. J. Stovner, G. Helde et al. (2001): Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover trial. *BMJ* 322, 19–22.
 122. Schulman, E., K. Dermott (2003): Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. *Headache* 43, 729–733.
 123. Silberstein, S. D. (1993): Headaches and women: Treatment of the pregnant and lactating migraineur. *Headache* 33, 533–540.
 124. Silberstein, S. D., R. B. Lipton (1996): Headache epidemiology. Emphasis on migraine. *Neurological Clinics* 14, 421–434.
 125. Silberstein, S. D., S. D. Collins, H. Carlson et al. (2000a): Safety and efficacy of once-daily, extended-release divalproex sodium monotherapy for the prophylaxis of migraine headaches. *Cephalalgia* 20:269.
 126. Silberstein, S. D., for the US Headache Consortium (2000b): Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 55, 754–763.
 127. Silberstein, S. D., W. Neto, J. Schmitt et al. (2004): Topiramate in migraine prevention: results of a large controlled trial. *Arch. Neurol.* 61, 490–495.
 128. Solomon, G. D., R. K. Cade, J. A. Klapper et al. (1997): Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. *Neurology* 49, 1219–1225.

129. Sorensen, P. S., B. H. Larsen, M. J. K. Rasmussen et al. (1991): Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. *Headache* 31, 650–657.
130. Steiner, T. J., R. Joseph, C. Hedman et al. (1988): Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. *Headache* 28, 15–23.
131. Steiner, T. J., L. J. Findley, A. W. C. Yuen (1997): Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. *Cephalalgia* 17, 109–112.
132. Steiner, T. J., F. Ahmed, L. J. Findley et al. (1998): S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. *Cephalalgia* 18(5), 283–286.
133. Tepper, S. J., A. Cochran, S. Hobbs et al. (1998): Sumatriptan suppositories for the acute treatment of migraine. *Int. J. Clin. Pract.* 52, 31–35.
134. Tepper, S. J., G. A. Donnan, A. J. Dowson et al. (1999): A long-term study to maximise migraine relief with zolmitriptan. *Curr. Med. Research Opinion* 15, 254–271.
135. Tfelt-Hansen, P., B. Standnes, P. Kangasniemi et al. (1984): Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. *Acta Neurol. Scand.* 69, 1–8.
136. Tfelt-Hansen, P. (1993): Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. *Cephalalgia* 13, 238–244.
137. Tfelt-Hansen, P., P. Henry, L. J. Mulder et al. (1995): The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. *Lancet* 346, 923–926.
138. Tfelt-Hansen, P., J. Teall, F. Rodriguez et al. (1998): Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. *Headache* 38, 748–755.
139. Tfelt-Hansen, P., R. E. Ryan (2000): Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. *Neurology* 55 (Suppl. 2), S19-S24.
140. Tfelt-Hansen, P., P. R. Saxena, C. Dahlöf et al. (2000): Ergotamine in the acute treatment of migraine. A review and European consensus. *Brain* 123,9–18.
141. The Diclofenac-K/Sumatriptan Migraine Study Group (1999): Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. *Cephalalgia* 19, 232–240.
142. The Multinational Oral Sumatriptan Cafergot Comparative Study Group (1991): A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. *Eur. Neurol.* 31, 314–322.
143. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992): A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. *Eur. Neurol.* 32, 177–184.
144. The Subcutaneous Sumatriptan International Study Group (1991): Treatment of migraine attacks with sumatriptan. *N. Engl. J. Med.* 325, 316–321.
145. Tronvik, E., L. J. Stovner, G. Helde et al. (2002): Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. *JAMA* 289, 65–69.
146. Tulunay, F. C., H. Ergun, S. E. Gulmez et al. (2004): The efficacy and safety of dipyrone (Novalgine) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. *Funct. Neurol.* 19(3), 197–202.
147. Ueberall, M. A., D. Wenzel (1999): Intranasal sumatriptan for the acute treatment of migraine in children. *Neurology* 52, 1507–1510.
148. Vahedi, K., P. Taupin, R. Djomby et al. (2002): Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. *J. Neurol.* 249, 206–211.
149. van de Ven, L. L. M., C. L. Franke, P. J. Koehler et al. (1997): Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. *Cephalalgia* 17, 596–599.
150. Valentgas, P., J. A. Cole, J. Mo et al. (2004): Severe vascular events in migraine patients. *Headache* 44, 642–651.
151. Waelkens, J. (1984): Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. *Cephalalgia* 4, 85–90.
152. Walach, H., W. Haeusler, T. Lowes et al. (1997): Classical homeopathic treatment of chronic headaches. *Cephalalgia* 17, 119–126.
153. Walach, H., T. Lowes, D. Mussbach et al. (2000): The long term effects of homeopathic treatment of chronic headaches: 1 year follow up. *Cephalalgia* 20, 835–837.
154. Welch, K. M. A., N. T. Mathew, P. Stone et al. (2000): Tolerability of sumatriptan: clinical trials and post-marketing experience. *Cephalalgia* 20, 687–695.
155. Whitmarsh, T. E., D. M. Coleston-Shields, T. J. Steiner (1997): Double-blind randomized placebo-controlled study of homeopathic prophylaxis of migraine. *Cephalalgia* 17, 600–604.
156. Winner, P., J. R. Saper, R. Nett et al. (1999): Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs. *Pediatrics* 104, 694–695.
157. Winner, P., D. Lewis, H. Visser et al. (2002): Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. *Headache* 42, 49–55.
158. Wörz, R., B. Reinhardt-Benmalek, K. H. Grottemeyer et al. (1991): Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura - a randomized double-blind cross-over multicenter study. *Cephalalgia* 11 Suppl. 11, 152–153.
159. Ziegler, D. K., A. Hurwitz, R. S. Hassanein (1987): Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch. Neurol.* 44, 486–489.